{{Drugbox
| IUPAC_name = 1-[2,5-Dimethoxy-(propan-2-yl)phenyl]propan-2-amine
| image = DOiPR_structure.png
| width = 200px

<!--Identifiers-->
| legal_CA = Schedule I
| legal_UK = Class A
| CAS_number_Ref =
| CAS_number = 42306-96-7
| CAS_supplemental = <br>{{CAS|53581-56-9}} ([[hydrochloride]] salt)
| PubChem = 44265275
| ChemSpiderID_Ref =
| ChemSpiderID = 23108724

<!--Chemical data-->
| C=14 | H=23 | N=1 | O=2
| molecular_weight =
| smiles = COC1=C(C=C(C(=C1)C(C)C)OC)CC(C)N
| StdInChI_Ref =
| StdInChI = 1S/C14H23NO2/c1-9(2)12-8-13(16-4)11(6-10(3)15)7-14(12)17-5/h7-10H,6,15H2,1-5H3
| StdInChIKey_Ref =
| StdInChIKey = UEEAUFJYLUJWQJ-UHFFFAOYAM
}}
'''2,5-Dimethoxy-4-isopropylamphetamine''' (also known as '''DOiP''' and '''DOiPr''') is a [[psychedelic drug|psychedelic]] [[drug]] of the [[substituted phenethylamine|phenethylamine]] and [[substituted amphetamine|amphetamine]] [[chemical class]]es.<ref>{{cite journal | url=http://pubs.acs.org/doi/abs/10.1021/bk-1989-0413.ch018 | title=Interaction of phenylisopropylamines with central 5-HT2 receptors. Analysis by quantitative structure-activity relationships. |author1=Richard A. Glennon |author2=Mark R. Seggel | journal=ACS Symposium Series |date=November 1989  | volume=413 | pages=264–280 | doi=10.1021/bk-1989-0413.ch018}}</ref><ref>{{cite journal | url=http://pubs.acs.org/doi/abs/10.1021/jm00165a023 | title=A structure-affinity study of the binding of 4-substituted analogs of 1-(2,5-dimethoxyphenyl)-2-aminopropane at 5-HT2 serotonin receptors |author1=Mark R. Seggel |author2=M. Y. Yousif |author3=Robert A. Lyon |author4=Milt Titeler |author5=Bryan L. Roth |author6=Eva A. Suba |author7=Richard A. Glennon | journal=Journal of Medicinal Chemistry |date=March 1990  | volume=33 | issue=3 | pages=1032–1036 | doi=10.1021/jm00165a023 | pmid=2308135}}</ref><ref>{{cite journal | url=http://pubs.acs.org/doi/abs/10.1021/jm00256a016 | title=Structure-activity relations in psychotomimetic phenylalkylamines |author1=F. A. B. Aldous |author2=B. C. Barrass |author3=K. Brewster |author4=D. A. Buxton |author5=D. M. Green |author6=R. M. Pinder |author7=P. Rich |author8=M. Skeels |author9=K. J. Tutt | journal=Journal of Medicinal Chemistry |date=October 1974  | volume=17 | issue=10 | pages=1100–1111 | doi=10.1021/jm00256a016 | pmid=4418757}}</ref> It was first [[Organic synthesis|synthesized]] by [[Alexander Shulgin]], and was described in his book ''[[PiHKAL]]'' (''Phenethylamines i Have Known And Loved''). Shulgin described DOiPR as being at least an order of magnitude weaker than [[2,5-Dimethoxy-4-propylamphetamine|DOPr]], with doses of 20–30&nbsp;mg required to produce valid changes in mental state.<ref name="PiHKAL">{{cite web | url=http://isomerdesign.com/PiHKAL/read.php?domain=pk&id=71 | title=PiHKAL: A Chemical Love Story #71 DOPR | publisher=Transform Press | date=September 1991 | accessdate=27 June 2015 |author1=Shulgin, Alexander |author2=Shulgin, Ann | pages=978}}</ref>
Very little data exists about the pharmacological properties, metabolism, and toxicity of DOiPR.

==See also==
* [[2C-iP]]
* [[2C-T-4]]
* [[DOx]]

==References==
{{Reflist|2}}

{{Hallucinogens}}
{{Serotonergics}}
{{Phenethylamines}}

{{DEFAULTSORT:Dimethoxy-4-isopropylamphetamine, 2,5-}}
[[Category:Substituted amphetamines]]
[[Category:Designer drugs]]
[[Category:Serotonin receptor agonists]]


{{hallucinogen-stub}}